NCT06521476View on ClinicalTrials.gov

Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
Central Sleep Apnea Comorbid With Opioid Use
Interventions
DRUG

Acetazolamide

Oral acetazolamide 250 mg daily for 7 days

DRUG

Placebo

Oral placebo daily for 7 days

Trial Locations (1)

15213

RECRUITING

University of Pittsburgh, Pittsburgh

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Sanjay R Patel

OTHER

NCT06521476 - Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder | Biotech Hunter | Biotech Hunter